This document describes an enantioselective and practical synthesis of the HIV-1 reverse transcriptase inhibitor efavirenz (1) in 62% overall yield over seven steps. A key step is an enantioselective addition of Li-cyclopropyl acetylide (4a) to p-methoxybenzyl-protected ketoaniline 3a, mediated by (1R,2S)-N-pyrrolidinylnorephedrine lithium alkoxide (5a), that establishes the stereogenic center of efavirenz with high stereocontrol (96-98% ee). The synthesis proceeds through preparation of starting materials, an optimized enantioselective alkynylation reaction, and subsequent transformations